Peripheral transcriptomic biomarkers for early detection of sporadic Alzheimer disease?

ABSTRACT: Alzheimer disease (AD) is the major epidemic of the 21st century, its prevalence rising along with improved human longevity. Early AD diagnosis is key to successful treatment, as currently available therapeutics only allow small benefits for diagnosed AD patients. By contrast, future therapeutics, including those already in preclinical or clinical trials, are expected to afford neuroprotection prior to widespread brain damage and dementia. Brain imaging technologies are developing as promising tools for early AD diagnostics, yet their high cost limits their utility for screening at-risk populations. Blood or plasma transcriptomics, proteomics, and/or metabolomics may pave the way for cost-effective AD risk screening in middle-aged individuals years ahead of cognitive decline. This notion i

SUBMITTER: Hadar A 

PROVIDER: S-EPMC6436957 | biostudies-literature | 2018 Dec

REPOSITORIES: biostudies-literature